Amylyx ALS drug failure leaves patients, advocates, and researchers reeling; In surprise move, FDA calls for advisory committee on Lilly’s Alzheimer’s drug

Taking stock of the drug industry, from the lab to the medicine chest

March 8, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Amylyx Pharmaceuticals via AP STAT+ | Amylyx ALS drug failure leaves patients, advocates, and researchers reeling — and wondering what's next The failure of Relyvrio, an ALS drug made by Amylyx Pharmaceuticals, raises tough questions for the patients, disease advocates, and the FDA. By Adam Feuerstein and Damian Garde STAT+ | In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug While Lilly had previously said a regulatory decision was expected by the end of 2023, it had already pushed that back to the first quarter of 2024. By Andrew Joseph STAT+ | Biden's SOTU highlights pharma's biggest political problem: It is terrifyingly, awfully alone Pharma used to rely on the support of pro-business Republicans, with occasional backing from pro-science Democrats in some states. No more. By Matthew Herper Adobe STAT+ | Opinion: It's time to rethink everything about our approach to psychiatric drug development We are at risk of killing green shoots in psychiatric drug development if we don't rethink everything about our current approach. By Amit Etkin STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser